Why I'm Backing Up the Truck on Biotech

A buy signal you can't ignore ... October 27, 2014 Archives | Unsubscribe     Why I'm Backing Up the Truck on Biotech   A buy signal you can't ignore Attacking new highs Plus: Noisy data can't tell the truth   Greg Guenthner coming to you from Baltimore, MD... Greg Guenthner That bright neon sign you're looking at is biotech, flashing, buy me! So put down your morning joe. Go ahead, do it. And ignore all incoming e-mail for the next few minutes. Because the biotech breakout has arrived-- and it can make you a bundle over the next few months. That's right. Forget about this month's stock roller coaster ride. Yeah, sure, it was painful for some. But it's time to hop aboard biotech... I can see you there right now, arms crossed, getting up in my grill: 'Oh, yeah, Guenthner? I just lost a bunch of dough on stocks. You think my wife's gonna let me buy biotech now?' I get it, man. Really, I do. But seriously, hear me out... This is all you need to know: biotech stocks are on a tear right now. They've shot up a staggering 12% since October 15th. That's an insane move in such a short time. And they've got all kinds of room to run. In fact, with many important names hitting new highs right now, biotech could be the best performing sector on the market for the rest of 2014. Truth is, most investors are still tucked in the fetal position after all the recent market chaos, begging for mommy. CNN Money's "Fear & Greed Index" is still stuck in extreme fear territory. No one's thinking about backing up the truck right now. That's why this is the perfect time to strike. Why? Because no one makes money begging for mommy. No one. And as I'm about to show you, the surge in biotech has nothing to do with the Ebola scare. This breakout won't fizzle when the Ebola breakout does. Bottom line: if you want to rake in serious gains this quarter -- and beyond-- the biotech comeback is the way to go. Let's take a step back and look at what happened with biotech earlier this year. It's important for us today... At the very beginning of 2014, biotechs went on a tear. The sector posted 30%-plus gains during the first eight weeks of the year. Every other day, a different biotech would easily rise double-digits. And while this was an active trader's paradise, these stocks got a little too big for their britches. Too much...and too quick. Sure enough, in March and April, they got hammered. But we noticed the glint of some shiny bright nuggets among the ruins. We even pinpointed the strong gust that let you ride the biotech thermals toward new highs in early June. And wouldn't you know it...just a few weeks after we alerted you to the biotech comeback, these stocks returned to winning territory. Since we first highlighted the June comeback, the Biotech iShares have risen an impressive 17%. (No, I don't have a crystal ball, even though it seems like it sometimes). And during the summer doldrums - usually the weakest time of the year - biotech shares easily beat the major averages. The summer bounce boosted the biotech sector to gains of more than 12% on the year. And that includes the major spring pullback. Biotech stocks beat the pants off the S&P 500 over that period, which gained just 5.5%. And today... The biotech sector might be the strongest tailwind pushing the stock market higher. Like I said, biotech stocks overall have risen a staggering 12% since October 15th.In fact, these stocks are breaking out just like they did back in early June when they went on their double-digit run. Take a look... Even more importantly, this biotech comeback is NOT all about the Ebola scare. Obviously, stocks related to the Ebola outbreak have been especially volatile over the past couple of weeks, as the virus has planted its flag on American soil. No, the biotech stocks attracting the smart money right now are the big boys. These are the household names such as Amgen, Gilead Sciences, and Celgene that are driving the train here. These biotech flagships are buys today as the entire sector continues to break out to new highs. Expect to hold them for a few months or more. Then count your money.         5 Tiny Companies to Change the World *This presentation goes offline at midnight, October 28* Five small companies with enormous potential are on the verge of changing the way we live... and you could be one of the first to find out how to turn their success into ultra-wealth. Click here now for details.           Rude Numbers Targets, Predictions and Wild Guesses   $11 billion worth of stock buybacks were just authorized by drug giant Pfizer. According to media reports, the new round of buybacks is "deflating expectations that Pfizer will make a new bid for AstraZeneca." $79.53 buys a barrel of oil this morning. Crude is starting off its week on the wrong foot, dropping more than 1% in early trading... $3.57 is the price of natural gas this morning. Natty is dropping right alongside oil today. It's down more than 1.3%... $1,231 marks the spot for gold futures. The yellow metal is treading water today after dropping nearly $20 late last week... 1,950 is where you'll find S&P futures just before the bell. Stocks are looking to open in the red to start the trading week...     Rude Trends When to Buy... When to Sell   Last week, I told you to ignore the existing home sales and new home sales data. The backward-looking data won't have much bearing our trade, anyway. It's all just noise. And after this recent round of data, you can see why... Late last week, the new homes sales numbers hit the Street. Sales rose in September after a banner August (that's good, right?). But check out the actual numbers. Sales of new single-family homes rose 0.2% last month. That sounds reasonable. But here come the revisions... August sales numbers were revised. So were June and July numbers. And check out this gem from the Wall Street Journal: The Commerce Department's estimates for new-home sales can be volatile from month to month. September's 0.2% gain came with a margin of error of 15.7 percentage points. 15.7%?!? So why should I even waste my time with the month-to-month fluctuations? I can't stress this enough: Let the rest of the investing world confuse themselves with these numbers. We'll continue making money by relying on the one indicator that's never revised: price. [Ed. Note: Send your feedback here: rude@agorafinancial.com - and follow me on Twitter: @GregGuenthner]     Ignore At Your Own Peril Today's Must Read Links   Oil-Industry Veteran Reveals 6 Plays to Get Rich Fast *o***id** S**v**: Declassified Ebola Cure? Prediction: Largest Economic Opportunity of the 21st Century     BE SURE TO ADD rude@agorafinancial.com to your address book.       Additional Articles & Commentary: Join the conversation! Follow us on social media:         The Rude Awakening is committed to protecting and respecting your privacy. We do not rent or share your email address. By submitting your email address, you consent to Agora Financial delivering daily email issues and advertisements. To end your Rude Awakening e-mail subscription and associated external offers sent from The Rude Awakening, click here. Please read our Privacy Statement. For any further comments or concerns please email us at rude@agorafinancial.com. If you are you having trouble receiving your Rude Awakening subscription, you can ensure its arrival in your mailbox by whitelisting The Rude Awakening. © 2014 Agora Financial, LLC. 808 Saint Paul Street, Baltimore MD 21202. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice. We expressly forbid our writers from having a financial interest in any security they personally recommend to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.